Legal Settlements and Loss Contingencies	9 Months Ended
Sep. 30, 2025
Legal Settlements and Loss Contingencies	NOTE 9 – Legal settlements and loss contingencies: In the third quarter of 2025, Teva recorded expenses of $60 million in legal settlements and loss contingencies, compared to expenses of $450 million in the third quarter of 2024. Expenses in the third quarter of 2025 were mainly related to an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments). Expenses in the third quarter of 2024 were mainly related to a decision by the European Commission in its antitrust investigation into COPAXONE ® , and an update to the estimated settlement provision for the opioid cases (mainly related to the settlement agreement with the city of Baltimore and the effect of the passage of time on the net present value of the discounted payments). See note 10. In the first nine months of 2025, Teva recorded expenses of $312 million in legal settlements and loss contingencies, compared to $638 million in the first nine months of 2024. Expenses in the first nine months of 2025 were mainly related to an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments), an update to the estimated provision recorded for the claims brought by attorneys general representing states and territories throughout the United States in the generic drug antitrust litigation, as well as a provision recorded in connection with the antitrust litigation related to QVAR. Expenses in the first nine months of 2024 were mainly related to a decision by the European Commission in its antitrust investigation into COPAXONE, and an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments and the settlement agreement with the city of Baltimore). As of September 30, 2025 and December 31, 2024, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $4,668 million and $4,881 million, respectively.

Legal Settlements and Loss Contingencies

9 Months Ended

Sep. 30, 2025

Legal Settlements and Loss Contingencies

NOTE 9 – Legal settlements and loss contingencies:

In the third quarter of 2025, Teva recorded expenses of $60 million in legal settlements and loss contingencies, compared to expenses of $450 million in the third quarter of 2024. Expenses in the third quarter of 2025 were mainly related to an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments). Expenses in the third quarter of 2024 were mainly related to a decision by the European Commission in its antitrust investigation into COPAXONE

, and an update to the estimated settlement provision for the opioid cases (mainly related to the settlement agreement with the city of Baltimore and the effect of the passage of time on the net present value of the discounted payments). See note 10.

In the first nine months of 2025, Teva recorded expenses of $312 million in legal settlements and loss contingencies, compared to $638 million in the first nine months of 2024. Expenses in the first nine months of 2025 were mainly related to an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments), an update to the estimated provision recorded for the claims brought by attorneys general representing states and territories throughout the United States in the generic drug antitrust litigation, as well as a provision recorded in connection with the antitrust litigation related to QVAR. Expenses in the first nine months of 2024 were mainly related to a decision by the European Commission in its antitrust investigation into COPAXONE, and an update to the estimated settlement provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments and the settlement agreement with the city of Baltimore).

As of September 30, 2025 and December 31, 2024, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses and other taxes and long-term liabilities was $4,668 million and $4,881 million, respectively.